The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: Results of an observational study

Multiple Sclerosis Journal

Volumn 17, Issue 2, 2011, Pages 192-197

  Fernández, Oscar ^a   Papais Alvarenga, Marcos ^a   Guerrero, Miguel ^a   León, Antonio ^a   Alonso, Ana ^a   López Madrona, Jose Carlos ^a   Leyva, Laura ^a   Oliver, Begoña ^a   De Ramón, Enrique ^a   Luque, Gloria ^a   Fernández, Victoria ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

natalizumab; relapsing remitting multiple sclerosis; secondary progressive multiple sclerosis

Indexed keywords

METHYLPREDNISOLONE; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; RECURRENT DISEASE; URINARY TRACT INFECTION;

EID: 79951541831     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510385507     Document Type: Article

References (19)

1. Pugliatti M., Rosati G., Carton H., et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006 ; 13: 700-722. (Pubitemid 44143944)
2. Lublin FD and Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 ; 46: 907-911.
3. Confavreux C. and Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006 ; 129: 606-616. (Pubitemid 43278223)
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 911-923.
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 655-661.
6. PRISMS (Prevention of Relapses and Disability by Interferon ß-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon ß-1a in relapsing/remitting multiple sclerosis. Lancet 1998 ; 352: 1498-1504.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996 ; 39: 285-294. (Pubitemid 26100751)
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 ; 45: 1268-1276.
9. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 ; 58: 169-178. (Pubitemid 34086933)
10. Polman CH, O'Connor PW, Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
11. Putzki N., Yaldizli O., Bühler R., Schwegler G., Curtius D. and Tettenborn B. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 2010 ; 63: 101-106.
12. Prosperini L., Borriello G., Fubelli F., Marinelli F. and Pozzilli C. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci 2010 ; Jun 10. Accessed 07 Nov 2010 [Epub ahead of print].
13. Oturai AB, Koch-Henriksen N., Petersen T., Jensen PE, Sellebjerg F. and Sorensen PS Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009 ; 16: 420-423.
14. Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 ; 13: 227-231. (Pubitemid 13158528)
15. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003 ; 348: 15-23. (Pubitemid 36026342)
16. Yaldizli ü. and Putzki N. Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord 2009 ; 2: 115-128.
17. Press release from European Medicines Agency, 21 January 2010. Available from http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/3760710en.pdf (accessed 2 February 2010 ).
18. Questions and answers on the review of Tysabri, European Medicines Agency, 21 January 2010. Available from http://www.ema.europa.eu/humandocs/PDFs/ EPAR/tysabri/Tysabri-A20-29-Q&A.pdf (accessed 2 February 2010 ).
19. Calabresi PA, Giovannoni G., Confavreux C., et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007 ; 69: 1391-1403. (Pubitemid 47511460)